Biological heterogeneity of primary cancer-associated fibroblasts determines the breast cancer microenvironment.

Cancer associated fibroblasts breast cancer oncology primary cell lines tumor microenvironment

Journal

American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944

Informations de publication

Date de publication:
2022
Historique:
received: 15 07 2022
accepted: 28 08 2022
entrez: 13 10 2022
pubmed: 14 10 2022
medline: 14 10 2022
Statut: epublish

Résumé

Cancer-associated fibroblasts are a highly heterogeneous group of cells whose phenotypes and gene alterations are still under deep investigation. As a part of tumor microenvironment, they are the focus of a growing number of studies. Cancer-associated fibroblasts might become a new target of breast cancer therapy, but still more tests and analyses are needed to understand mechanisms and interactions between them and breast cancer cells. The study aimed to isolate cancer associated fibroblasts from breast cancer tissue and to phenotype the isolated cell lines. We focused on various cancer-associated fibroblast characteristic biomarkers and those that might differentiate various cancer-associated fibroblasts' subtypes. Patients with a histological diagnosis of invasive breast cancer (diameter ≤15 mm) and qualified for primary surgical treatment were enrolled in the study. Cell lines were isolated from breast cancer biopsy. For the phenotyping, we used flow cytometry, immunofluorescence and RT-qPCR analysis. Based on our study, there was no indication of a clear pattern in the cancer-associated fibroblasts' classification. Results of cancer-associated fibroblasts expression were highly heterogeneous, and specific subtypes were not defined. Moreover, comparing cancer-associated fibroblasts divided into groups based on BC subtypes from which they were isolated also did not allow to notice of any clear pattern of expressions. In the future, a higher number of analyzed cancer-associated fibroblast cell lines should be investigated to find expression schemes.

Identifiants

pubmed: 36225645
pmc: PMC9548006

Types de publication

Journal Article

Langues

eng

Pagination

4411-4427

Informations de copyright

AJCR Copyright © 2022.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int Rev Cell Mol Biol. 2009;276:161-214
pubmed: 19584013
Sci Rep. 2017 Apr 21;7:46662
pubmed: 28429795
Expert Opin Ther Targets. 2005 Dec;9(6):1217-33
pubmed: 16300472
J Exp Med. 2020 Aug 3;217(8):
pubmed: 32434219
J Immunol. 2006 Nov 1;177(9):5968-79
pubmed: 17056521
Front Oncol. 2015 Jul 27;5:158
pubmed: 26284191
Int J Oncol. 2005 Jul;27(1):121-9
pubmed: 15942651
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
J Cell Mol Med. 2017 Sep;21(9):1979-1988
pubmed: 28523716
Clin Cancer Res. 2017 Apr 1;23(7):1710-1721
pubmed: 27702820
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16002-7
pubmed: 21911392
Cell Death Discov. 2020 Jun 2;6:42
pubmed: 32528731
Nat Commun. 2020 Jan 21;11(1):404
pubmed: 31964880
Histochem Cell Biol. 2016 Aug;146(2):205-17
pubmed: 27102177
Semin Cancer Biol. 2001 Apr;11(2):87-95
pubmed: 11322828
Br J Dermatol. 2006 Jun;154(6):1062-70
pubmed: 16704635
Cancer Res. 2007 Nov 1;67(21):10123-8
pubmed: 17974953
Integr Biol (Camb). 2015 Oct;7(10):1120-34
pubmed: 25959051
Ann Surg Oncol. 2019 Dec;26(13):4791-4804
pubmed: 31583548
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
PLoS One. 2013 Oct 29;8(10):e77166
pubmed: 24204762
Pathol Res Pract. 2020 May;216(5):152915
pubmed: 32146002
Nat Commun. 2018 Dec 4;9(1):5150
pubmed: 30514914
Surg Oncol Clin N Am. 2018 Jan;27(1):95-120
pubmed: 29132568
Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):2037-46
pubmed: 7583587
Adv Med Sci. 2015 Sep;60(2):264-72
pubmed: 26057860
Cancer Lett. 2015 Nov 1;368(1):7-13
pubmed: 26276713
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Cancer Cell. 2004 Jul;6(1):17-32
pubmed: 15261139
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9
pubmed: 2402505
Cell. 2018 Feb 8;172(4):841-856.e16
pubmed: 29395328
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
Front Cell Dev Biol. 2021 Jul 22;9:711381
pubmed: 34395440
J Biomed Nanotechnol. 2018 Oct 1;14(10):1826-1835
pubmed: 30041728
Eur J Immunol. 1981 Aug;11(8):597-603
pubmed: 7274325
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Cytotechnology. 2009 Jan;59(1):31-44
pubmed: 19296231
Cytometry A. 2018 Jul;93(9):941-951
pubmed: 28383825
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Int J Mol Sci. 2021 Oct 27;22(21):
pubmed: 34769066
Adv Anat Pathol. 2011 Jul;18(4):255-67
pubmed: 21654357
Physiol Rev. 2021 Jan 1;101(1):147-176
pubmed: 32466724
Dis Markers. 2016;2016:4218989
pubmed: 27881889
Scand J Clin Lab Invest. 2008;68(3):192-203
pubmed: 17852829
Cancers (Basel). 2020 Oct 24;12(11):
pubmed: 33114328
Cancers (Basel). 2019 Dec 18;12(1):
pubmed: 31861498
Oncotarget. 2017 Mar 28;8(13):20741-20750
pubmed: 28186964
Biochimie. 1987 Apr;69(4):315-20
pubmed: 2888493
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Cancers (Basel). 2021 Nov 02;13(21):
pubmed: 34771664
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):82-5
pubmed: 11388749
Oncol Lett. 2018 May;15(5):6195-6202
pubmed: 29616101
Cancers (Basel). 2019 Oct 17;11(10):
pubmed: 31627350
Nature. 2011 Dec 07;481(7379):85-9
pubmed: 22158103
Stem Cells. 2014 Jan;32(1):145-56
pubmed: 24395741
Cancer Biol Ther. 2006 Dec;5(12):1640-6
pubmed: 17106243
Blood. 2007 Apr 15;109(8):3570-8
pubmed: 17185465
Br J Cancer. 2020 Mar;122(7):931-942
pubmed: 31992854

Auteurs

Marika Musielak (M)

Department of Electroradiology, Poznan University of Medical Sciences Poznan, Poland.
Doctoral School, Poznan University of Medical Sciences Poznan, Poland.
Radiobiology Laboratory, Department of Medical Physics, Greater Poland Cancer Centre Poznan, Poland.

Oliwia Piwocka (O)

Radiobiology Laboratory, Department of Medical Physics, Greater Poland Cancer Centre Poznan, Poland.
Faculty of Biology, Adam Mickiewicz University Poznan, Poland.

Katarzyna Kulcenty (K)

Radiobiology Laboratory, Department of Medical Physics, Greater Poland Cancer Centre Poznan, Poland.

Karolina Ampuła (K)

Radiobiology Laboratory, Department of Medical Physics, Greater Poland Cancer Centre Poznan, Poland.
Faculty of Biology, Adam Mickiewicz University Poznan, Poland.

Beata Adamczyk (B)

Breast Surgical Oncology Department, Greater Poland Cancer Centre Poznan, Poland.

Igor Piotrowski (I)

Department of Electroradiology, Poznan University of Medical Sciences Poznan, Poland.
Radiobiology Laboratory, Department of Medical Physics, Greater Poland Cancer Centre Poznan, Poland.

Magdalena Fundowicz (M)

Radiotherapy Ward I, Greater Poland Cancer Centre Poznan, Poland.

Marta Kruszyna-Mochalska (M)

Department of Electroradiology, Poznan University of Medical Sciences Poznan, Poland.
Medical Physics Department, Greater Poland Cancer Centre Poznan, Poland.

Wiktoria M Suchorska (WM)

Department of Electroradiology, Poznan University of Medical Sciences Poznan, Poland.
Radiobiology Laboratory, Department of Medical Physics, Greater Poland Cancer Centre Poznan, Poland.

Julian Malicki (J)

Department of Electroradiology, Poznan University of Medical Sciences Poznan, Poland.
Medical Physics Department, Greater Poland Cancer Centre Poznan, Poland.

Classifications MeSH